LIV Emles at Home ETF

Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, it has agreed to exclusively license "Use of Spirostenols to treat Mitochondrial Disorders" from Georgetown University. Mitochondria are specialized compartments present in every cell of the body, except red blood cells and are responsible for generating over 90% of the energy needed to sustain life. Diseases thought to involve mitochondria impairment are Alzheimer's, Parkinson's, Multiple Sclerosis, and conditions such as, neuronal death induced by stroke, traumatic brain injury, seizures and spinal cord injury, among many others. Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "We are extremely pleased with our collaboration with Georgetown University, it gives us the ability to continually, build and grow, our pipeline of innovative drugs. The future, and our future, is dependent on innovation, and I feel 100% confident our shareholders will be kindly rewarded for being patient with us as we build and grow Samaritan." Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan Pharmaceuticals is a drug development company driven to discover, develop, and commercialize, innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease. Samaritan, in collaboration with Georgetown University, is advancing eight promising compounds, out of its rich pipeline of 250 possible drug candidates, all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.